Основная статистика
| LEI | 54930070006GPKFYZ813 |
| CIK | 1631574 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Wave Life Sciences Ltd.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| September 3, 2025 |
Wave Life Sciences Announces Positive Update from Ongoing EX-99.1 Exhibit 99.1 Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT) First-ever demonstration of therapeutically restored physiol |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commiss |
|
| August 11, 2025 |
WAVE LIFE SCIENCES LTD. 2021 EQUITY INCENTIVE PLAN, AS AMENDED EX-10.1 Exhibit 10.1 Effective Date: August 5, 2025 WAVE LIFE SCIENCES LTD. 2021 EQUITY INCENTIVE PLAN, AS AMENDED 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the Wave Life Sciences Ltd. 2021 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (i) provide eligible Employees, Consultants, and Directors with the opportunity to acquire a proprietary interest |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commission |
|
| August 5, 2025 |
EX-99.1 Exhibit 99.1 Wave Life Sciences Corporate Presentation August 5, 2025 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and developmen |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commission |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore (State or other jurisdiction of incorporation) 001-37627 (Commission File Number |
|
| July 30, 2025 |
EX-99.1 Exhibit 99.1 Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete i |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37627 WAVE LIFE SCI |
|
| June 23, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| May 8, 2025 |
Exhibit 99.1 Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongo |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37627 WAVE LIFE SC |
|
| May 8, 2025 |
Exhibit 99.2 Wave Life Sciences Corporate Presentation May 8, 2025 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, co |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-3762 |
|
| March 26, 2025 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commission |
|
| March 26, 2025 |
Wave Life Sciences Announces Positive Data from Exhibit 99.1 Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531 Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration ther |
|
| March 4, 2025 |
Exhibit 99.1 Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort Multi-dosing ongoing in 200 mg cohort of RestorAATion-2 clinical trial of WVE-006 in AATD with data expected in 2025; second single dose |
|
| March 4, 2025 |
Exhibit 19.1 WAVE LIFE SCIENCES LTD. (the “Company” or “Wave”) INSIDER TRADING POLICY (as of March 4, 2025) Important Notice: Notwithstanding anything to the contrary in this Insider Trading Policy, all transactions in Wave’s securities by Company Personnel (as defined on the next page) must be conducted pursuant to Rule 10b5-1 trading plans until further notice. This also includes transactions in |
|
| March 4, 2025 |
Description of Securities of the Registrant and Comparison of Shareholder Rights Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Wave Life Sciences Ltd. (the “Company,” “we,” “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our ordinary shares, no par value. DESCRIPTION OF SHARE CAPITAL General The following description o |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37627 WAVE LIFE SCIENCES LT |
|
| March 4, 2025 |
Corporate Presentation March 4, 2025 Wave Life Sciences Exhibit 99.2 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commission |
|
| January 13, 2025 |
Exhibit 99.1 Wave Life Sciences Corporate Presentation January 13, 2025 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plan |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commissi |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commiss |
|
| November 20, 2024 |
EX-99.1 Exhibit 99.1 Wave Life Sciences Corporate Presentation November 20, 2024 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and develop |
|
| November 12, 2024 |
Exhibit 4.5 FORM OF SENIOR INDENTURE WAVE LIFE SCIENCES LTD., ISSUER and , TRUSTEE INDENTURE Dated as of , 20 Senior Debt Securities CROSS-REFERENCE TABLE1 Section of Trust Indenture Act Section of Section of of 1939, as amended Indenture 310(a) 7.09 310(b) 7.08, 7.10 310(c) Inapplicable 311(a) 7.13 311(b) 7.13 311(c) Inapplicable 312(a) 5.01, 5.02(a) 312(b) 5.02(c) 312(c) 5.02(c) 313( |
|
| November 12, 2024 |
Exhibit 99.1 Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three wholly owned GalNAc-AIMer preclinical programs that offer first-in-class approaches to address unmet needs in cardiometabolic diseases WVE-007 (INHB |
|
| November 12, 2024 |
EX-5.3 Exhibit 5.3 One Financial Center Boston, MA 02111 617 542 6000 mintz.com November 12, 2024 Wave Life Sciences Ltd. 7 Straits View #12-00, Marina One East Tower Singapore, 018936 Ladies and Gentlemen: We have acted as U.S. counsel to Wave Life Sciences Ltd., a company incorporated under the laws of Singapore (the “Company”), in connection with the preparation and filing with the Securities a |
|
| November 12, 2024 |
Powers of Attorney (included on the signature page to this Registration Statement). As filed with the Securities and Exchange Commission on November 12, 2024 Registration No. |
|
| November 12, 2024 |
WVE / Wave Life Sciences Ltd. / Adage Capital Management, L.P. Passive Investment SC 13G/A 1 p24-3046sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)*, ** Wave Life Sciences Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) Y95308105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to d |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commiss |
|
| November 12, 2024 |
Powers of Attorney (included on the signature page to this registration statement). Table of Contents As filed with the Securities and Exchange Commission on November 12, 2024 Registration No. |
|
| November 12, 2024 |
Exhibit 10.1 AMENDMENT NO. 3 TO OPEN MARKET SALE AGREEMENT November 12, 2024 This Amendment No. 3 (“Amendment No. 3”) amends that certain Open Market Sale AgreementSM, dated as of May 10, 2019, as amended by Amendment No. 1, dated as of March 2, 2020, and Amendment No. 2, dated March 3, 2022 (collectively, the “Agreement”), by and between Wave Life Sciences Ltd. (the “Company”) and Jefferies LLC, |
|
| November 12, 2024 |
As filed with the Securities and Exchange Commission on November 12, 2024 As filed with the Securities and Exchange Commission on November 12, 2024 Registration No. |
|
| November 12, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Wave Life Sciences Ltd. |
|
| November 12, 2024 |
Form of Subordinated Indenture. Exhibit 4.6 FORM OF SUBORDINATED DEBT SECURITIES INDENTURE WAVE LIFE SCIENCES LTD. INDENTURE DATED AS OF , 20 TRUSTEE SUBORDINATED DEBT SECURITIES Table of Contents Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 4 ARTICLE |
|
| November 12, 2024 |
SC 13G/A 1 p24-3012sc13ga.htm WAVE LIFE SCIENCES LTD. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Wave Life Sciences Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) Y95308105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| November 12, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Wave Life Sciences Ltd. |
|
| November 12, 2024 |
Non-Employee Director Compensation Policy, as amended, effective as of August 6, 2024 Exhibit 10.2+ Effective: Upon the date of receipt of final voting results (August 12, 2024) evidencing requisite shareholder approval of non-employee director compensation proposal at 2024 Annual General Meeting through 2025 Annual General Meeting WAVE Life Sciences Ltd. 2024 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY A. Introduction The Board of Directors (the “Board”) of Wave Life Sciences Ltd. ( |
|
| November 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Wave Life Sciences Ltd. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37627 WAVE LIF |
|
| October 30, 2024 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commissi |
|
| October 30, 2024 |
Exhibit 99.1 Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commissi |
|
| October 16, 2024 |
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in EX-99.1 Exhibit 99.1 Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency Achieved proof-of-mechanism for Wave’s RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous “MZ” genotype with low risk of AATD lung and liver disease A single subcutaneou |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2024 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commissi |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2024 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commissio |
|
| October 1, 2024 |
WVE / Wave Life Sciences Ltd. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Wave Life Sciences Ltd. (Name of Issuer) $0 Par Value Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Nam |
|
| October 1, 2024 |
Exhibit 99.1 Wave Life Sciences Corporate Presentation October 1, 2024 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans |
|
| September 27, 2024 |
23,125,001 Ordinary Shares Pre-Funded Warrants to Purchase 1,875,023 Ordinary Shares 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263251 PROSPECTUS SUPPLEMENT (To Prospectus dated May 4, 2022) 23,125,001 Ordinary Shares Pre-Funded Warrants to Purchase 1,875,023 Ordinary Shares We are offering 23,125,001 of our ordinary shares and, in lieu of ordinary shares to certain investors that so choose, pre-funded warrants to purchase 1,875,023 ordinary shar |
|
| September 26, 2024 |
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and EX-99.1 Exhibit 99.1 Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants CAMBRIDGE, Mass., September 25, 2024 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today the pricing of its previously announce |
|
| September 26, 2024 |
Form of Pre-Funded Warrant (2024) EX-4.1 Exhibit 4.1 WAVE LIFE SCIENCES LTD. FORM OF PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES Number of Shares: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: September [ ], 2024 Wave Life Sciences Ltd., a company incorporated under the laws of the Republic of Singapore (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2024 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commis |
|
| September 26, 2024 |
Exhibit 1.1 23,125,001 Ordinary Shares Pre-Funded Warrants to Purchase 1,875,023 Ordinary Shares Wave Life Sciences Ltd. UNDERWRITING AGREEMENT September 25, 2024 J.P. MORGAN SECURITIES LLC LEERINK PARTNERS LLC As Representatives of the several Under writers c/o J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, New York 10179 c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massa |
|
| September 24, 2024 |
Wave Life Sciences Announces Positive Interim Data from Exhibit 99.1 Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified analysis; dystrophin was comprised of two isoforms consisten |
|
| September 24, 2024 |
PROSPECTUS SUPPLEMENT NO. 1 TO PROSPECTUS DATED MAY 4, 2022 Filed Pursuant to Rule 424(b)(3) Registration No. 333-263251 PROSPECTUS SUPPLEMENT NO. 1 TO PROSPECTUS DATED MAY 4, 2022 This Prospectus Supplement No. 1 supplements and amends the prospectus dated May 4, 2022 (the “Prospectus”), covering the offering, issuance and sale of up to a maximum aggregate offering amount of $131,974,010 (the “Maximum Offering Amount”) of our ordinary shares, no par value |
|
| September 24, 2024 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2024 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commis |
|
| September 24, 2024 |
SUBJECT TO COMPLETION, DATED SEPTEMBER 24, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263251 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2024 |
Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended Exhibit 10.1 Effective Date: August 6, 2024 WAVE LIFE SCIENCES LTD. 2021 EQUITY INCENTIVE PLAN, AS AMENDED 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the Wave Life Sciences Ltd. 2021 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (i) provide eligible Employees, Consultants, and Directors with the opportunity to acquire a proprietary interest, or oth |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37627 WAVE LIFE SCI |
|
| August 8, 2024 |
Form of Inducement Non-qualified Share Option Agreement, effective May 2024 Exhibit 10.1 Grant No. Wave Life Sciences Ltd. (the “Company”) Nasdaq Inducement Non-qualified Share Option Grant Notice and Nasdaq Inducement Non-qualified Share Option Agreement A. Name of Participant: B. Grant Date: C. Expiration Date: 10-year anniversary of the Grant Date D. Maximum Number of Ordinary Shares for which this Option is exercisable: E. Exercise (purchase) Price per Ordinary Share: |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commission |
|
| August 8, 2024 |
Form of Inducement Restricted Share Unit Agreement, effective May 2024 Exhibit 10.2 Grant. No. RSU- Wave Life Sciences Ltd. (the “Company”) Nasdaq Inducement Restricted Share Unit Award Grant Notice and Nasdaq Inducement Restricted Share Unit Agreement A. Name of Participant: B. Grant Date: C. Maximum Number of Shares Underlying Restricted Share Unit Award: D. Vesting Start Date: E. Vesting Schedule: This Restricted Share Unit Award shall vest as follows provided the |
|
| August 8, 2024 |
Exhibit 99.1 Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update Successful clinical translation of Wave’s RNA medicines platform in HD patients with WVE-003 provides further validation of Wave’s proprietary platform with PN and stereochemistry; opt-in package for WVE-003 submitted to partner Takeda and engagement with regulators initiated to discuss poten |
|
| August 8, 2024 |
Corporate Presentation August 8, 2024 Wave Life Sciences Exhibit 99.2 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, |
|
| June 25, 2024 |
Wave Life Sciences Announces Positive Results from Phase 1b/2a Exhibit 99.1 Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) pro |
|
| June 25, 2024 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commission |
|
| June 21, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37627 WAVE LIFE SC |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 9, 2024 |
Exhibit 99.1 Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update RestorAATion-2 clinical trial of WVE-006 in AATD patients underway; expected proof-of-mechanism data in patients with AATD remains on track for 2024 INHBE program for obesity expected clinical trial initiation in 1Q 2025; preclinical data demonstrate weight loss similar to semaglutide, fat los |
|
| May 9, 2024 |
Exhibit 99.2 Wave Life Sciences Corporate Presentation May 9, 2024 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, co |
|
| April 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commission |
|
| March 6, 2024 |
Clawback Policy, effective as of October 2, 2023 Exhibit 97.1 WAVE LIFE SCIENCES LTD. CLAWBACK POLICY I. Introduction The Board of Directors (the “Board”) of Wave Life Sciences Ltd. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has th |
|
| March 6, 2024 |
Description of Securities of the Registrant and Comparison of Shareholder Rights Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Wave Life Sciences Ltd. (the “Company,” “we,” “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our ordinary shares, no par value. DESCRIPTION OF SHARE CAPITAL General The following description o |
|
| March 6, 2024 |
EX-99.2 Corporate Presentation March 6, 2024 Wave Life Sciences Exhibit 99.2 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37627 WAVE LIFE SCIENCES LT |
|
| March 6, 2024 |
EX-99.1 Exhibit 99.1 Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and every-six-month or annual subcutaneous dosing; clinical trial initiation expec |
|
| February 14, 2024 |
EX-99.A 2 d628447dex99a.htm EX-99.A EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Ordinary Shares of Wave Life Sciences Ltd., dated as of February 14, 2024, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordanc |
|
| February 14, 2024 |
WVE / Wave Life Sciences Ltd. / MAVERICK CAPITAL LTD - SC 13G/A Passive Investment SC 13G/A 1 d628447dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Wave Life Sciences Ltd. (Name of Issuer) $0 Par Value Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| February 14, 2024 |
EX-99.B 3 d628447dex99b.htm EX-99.B EXHIBIT B Power of Attorney KNOW ALL MEN BY THESE PRESENTS, that I, Lee S. Ainslie III, hereby make, constitute and appoint Trevor Wiessmann as my agent and attorney-in-fact for the purpose of executing (i) in my personal capacity or (ii) in my capacity as manager or other officer or representative of Maverick Capital Management, LLC, Maverick Capital, Ltd. or a |
|
| February 14, 2024 |
SC 13G/A 1 wvea221424.htm 683 CAPITAL MANAGEMENT, LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Wave Life Sciences Ltd. (Name of Issuer) $0 par value Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) |
|
| February 13, 2024 |
WVE / Wave Life Sciences Ltd. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* WAVE LIFE SCIENCES LTD. (Name of Issuer) Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 12, 2024 |
SC 13G/A 1 p23-0362sc13ga.htm WAVE LIFE SCIENCES LTD. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Wave Life Sciences Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| February 7, 2024 |
SC 13G/A 1 p24-0577sc13ga.htm WAVE LIFE SCIENCES LTD. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Wave Life Sciences Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the a |
|
| February 6, 2024 |
WVE / Wave Life Sciences Ltd. / GLAXOSMITHKLINE PLC - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Wave Life Sciences Ltd. (Name of Issuer) $0 Par Value Ordinary Share (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commissio |
|
| January 8, 2024 |
EX-99.1 Exhibit 99.1 Wave Life Sciences Corporate Presentation January 8, 2024 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and developme |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commissio |
|
| December 15, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commiss |
|
| December 15, 2023 |
Wave Life Sciences Corporate Presentation December 15, 2023 Exhibit 99.1 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development pla |
|
| December 8, 2023 |
Exhibit 1.1 20,000,000 Ordinary Shares Wave Life Sciences Ltd. UNDERWRITING AGREEMENT December 6, 2023 J.P. MORGAN SECURITIES LLC LEERINK PARTNERS LLC As Representatives of the several Underwriters c/o J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, New York 10179 c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 Ladies and Gentlemen: Introductory. Wave Life |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commissi |
|
| December 8, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263251 PROSPECTUS SUPPLEMENT (To Prospectus dated May 4, 2022) 20,000,000 Ordinary Shares We are offering 20,000,000 of our ordinary shares. Our ordinary shares are listed on the Nasdaq Global Market under the symbol “WVE.” The last reported sale price of our ordinary shares on the Nasdaq Global Market on December 5, 2023 was |
|
| December 8, 2023 |
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares EX-99.1 Exhibit 99.1 Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares CAMBRIDGE, Mass., December 7, 2023 – Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of its previously announced underwritten public offering of 20,000,000 |
|
| December 6, 2023 |
SUBJECT TO COMPLETION, DATED DECEMBER 6, 2023 424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| November 9, 2023 |
As filed with the Securities and Exchange Commission on November 9, 2023 As filed with the Securities and Exchange Commission on November 9, 2023 Registration No. |
|
| November 9, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Wave Life Sciences Ltd. |
|
| November 9, 2023 |
Non-Employee Director Compensation Policy, effective as of August 7, 2023 Exhibit 10.1 Effective: Upon the date of receipt of final voting results (August 7, 2023) evidencing requisite shareholder approval of non-employee director compensation proposal at 2023 Annual General Meeting through 2024 Annual General Meeting WAVE Life Sciences Ltd. 2023 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY A. Introduction The Board of Directors (the “Board”) of Wave Life Sciences Ltd. (th |
|
| November 9, 2023 |
Exhibit 99.1 Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update Initiated RestorAATion clinical program for WVE-006, industry’s first-ever RNA editing clinical candidate, following approval of CTAs; dosing on track for 4Q 2023 and first-in-human proof-of-mechanism data anticipated in 2024 On track to deliver dystrophin data from potentially registrational |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore (State or other jurisdiction of incorporation) 001-37627 (Commission File Num |
|
| November 9, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Wave Life Sciences Ltd. |
|
| November 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commissi |
|
| November 9, 2023 |
As filed with the Securities and Exchange Commission on November 9, 2023 As filed with the Securities and Exchange Commission on November 9, 2023 Registration No. |
|
| November 9, 2023 |
Wave Life Sciences Corporate Presentation November 9, 2023 Exhibit 99.1 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plan |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37627 WAVE LIF |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commissio |
|
| October 2, 2023 |
Exhibit 99.1 Wave Life Sciences Corporate Presentation October 2, 2023 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans |
|
| September 28, 2023 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commis |
|
| September 28, 2023 |
EX-99.1 Exhibit 99.1 Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day Presented preclinical proof-of-concept data for new, wholly owned program targeting INHBE for metabolic disorders, including obesity, which uses Wave’s best-in-class GalNAc-siRNA capabilities and novel genetic insights from GSK WVE-006 – industry’s first-ever RNA edit |
|
| September 5, 2023 |
EX-99.1 Exhibit 99.1 Wave Life Sciences Corporate Presentation September 5, 2023 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and develop |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commiss |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commission |
|
| August 7, 2023 |
Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended Exhibit 10.1 Effective Date: August 1, 2023 WAVE LIFE SCIENCES LTD. 2021 EQUITY INCENTIVE PLAN, AS AMENDED 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the Wave Life Sciences Ltd. 2021 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (i) provide eligible Employees, Consultants, and Directors with the opportunity to acquire a proprietary interest, or oth |
|
| August 7, 2023 |
Wave Life Sciences Ltd. 2019 Employee Share Purchase Plan, as amended Exhibit 10.2 Effective Date: August 1, 2023 WAVE LIFE SCIENCES LTD. 2019 EMPLOYEE SHARE PURCHASE PLAN, AS AMENDED The following constitute the provisions of the 2019 Employee Share Purchase Plan, as amended (the “Plan”) of Wave Life Sciences Ltd. (the “Company”). 1. Purpose. The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purcha |
|
| August 3, 2023 |
EX-99.1 Exhibit 99.1 Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update Preparing for imminent submission of clinical trial applications (CTAs) for GalNAc-conjugated AATD candidate (WVE-006), the industry’s first RNA editing clinical candidate Novel DMD therapeutic candidate (WVE-N531) with best-in-class exon skipping clinical data is on track to enter a |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37627 WAVE LIFE SCI |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commission |
|
| August 3, 2023 |
Description of Securities of the Registrant and Comparison of Shareholder Rights Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Wave Life Sciences Ltd. (the “Company,” “we,” “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our ordinary shares, no par value. DESCRIPTION OF SHARE CAPITAL General The following description o |
|
| August 3, 2023 |
EX-99.2 Exhibit 99.2 Wave Life Sciences Corporate Presentation August 3, 2023 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and developmen |
|
| June 26, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 23, 2023 |
EX-99.1 2 d449265dex991.htm EX-99.1 Exhibit 99.1 Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated WVE-004 did not |
|
| May 23, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commission F |
|
| May 23, 2023 |
EX-99.2 Exhibit 99.2 Wave Life Sciences Corporate Presentation May 23, 2023 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development |
|
| May 5, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 3, 2023 |
EX-99.1 Exhibit 99.1 Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update Emerging leader in RNA medicines with multi-modal discovery and development platform and first-in-class RNA editing programs Rapidly advancing toward 2023 CTA submissions and first-in-human study for WVE-006, the industry’s first RNA editing clinical candidate Planning for potentially |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37627 WAVE LIFE SC |
|
| May 3, 2023 |
EX-99.2 Wave Life Sciences Corporate Presentation May 3, 2023 Exhibit 99.2 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development p |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| March 23, 2023 |
Exhibit 10.12 EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), made and entered into as of November 8, 2022, by and between Wave Life Sciences USA, Inc., a Delaware corporation (“Company”) and a wholly owned subsidiary of Wave Life Sciences Ltd., a Singapore corporation (the “Parent Company”), and Chris Francis (“Executive”). WHEREAS, Company wishes to continue to employ |
|
| March 23, 2023 |
Exhibit 10.5 INVESTOR AGREEMENT By and Between GLAXO GROUP LIMITED AND WAVE LIFE SCIENCES LTD. Dated as of January 26, 2023 TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 6 2.1 Demand Registration. 6 2.2 Piggyback Registration 8 2.3 Registration Expenses 9 2.4 Registration Procedures 10 2.5 Holders’ Obligations 13 2.6 Blackout Provisions 13 2.7 Indemnification 14 2.8 Limitations on |
|
| March 23, 2023 |
Exhibit 10.4 SHARE PURCHASE AGREEMENT By and Between GLAXO GROUP LIMITED AND WAVE LIFE SCIENCES LTD. Dated as of December 13, 2022 TABLE OF CONTENTS Page 1. Definitions 1 1.1 Defined Terms 1 1.2 Additional Defined Terms 4 2. Purchase and Sale of Shares 4 3. Closing Date; Deliveries 5 3.1 Closing Date 5 3.2 Deliveries 5 4. Representations and Warranties of the Company 6 4.1 Organization, Good Stand |
|
| March 23, 2023 |
Exhibit 10.3 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Collaboration And License Agreement by and among Wave Life Sciences USA, Inc., Wave Life Sciences UK Limited and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 3) LIMITED December 13, 2022 Table o |
|
| March 23, 2023 |
Description of Securities of the Registrant and Comparison of Shareholder Rights Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Wave Life Sciences Ltd. (the “Company,” “we,” “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our ordinary shares, no par value. DESCRIPTION OF SHARE CAPITAL General The following description o |
|
| March 23, 2023 |
Power of Attorney (included on signature page to the Original 10-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37627 WAVE LIFE SCIENCES LT |
|
| March 22, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 98-1356880 (State or other jurisdiction of incorporation) (Commission |
|
| March 22, 2023 |
EX-99.1 Exhibit 99.1 Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic Extended leadership in RNA editing and advanced WVE-006 for AATD – first-in-class RNA editing candidate t |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 1)* Wave Life Sciences Ltd. (Name of Issuer) $0 par value Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2022 (Date of Event whi |
|
| February 14, 2023 |
WVE / Wave Life Sciences Ltd / MAVERICK CAPITAL LTD - SC 13G/A Passive Investment SC 13G/A 1 d430000dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Wave Life Sciences Ltd. (Name of Issuer) Ordinary Shares, $0 Par Value (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 14, 2023 |
WVE / Wave Life Sciences Ltd / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d400612dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* WAVE LIFE SCIENCES LTD. (Name of Issuer) Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to de |
|
| February 14, 2023 |
EX-99.B 2 d400612dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
EX-99.B 3 d430000dex99b.htm EX-99.B EXHIBIT B Power of Attorney KNOW ALL MEN BY THESE PRESENTS, that I, Lee S. Ainslie III, hereby make, constitute and appoint Mark Gurevich as my agent and attorney-in -fact for the purpose of executing (i) in my personal capacity or (ii) in my capacity as manager or other officer or representative of Maverick Capital Management, LLC, Maverick Capital, Ltd. or any |
|
| February 14, 2023 |
EX-99.A 2 d430000dex99a.htm EX-99.A EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Ordinary Shares of Wave Life Sciences Ltd., dated as of February 14, 2023, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordanc |
|
| February 10, 2023 |
SC 13G/A 1 p23-0786sc13ga.htm WAVE LIFE SCIENCES LTD. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Wave Life Sciences Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| January 30, 2023 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2023 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commissi |
|
| January 30, 2023 |
WVE / Wave Life Sciences Ltd / GLAXOSMITHKLINE PLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Wave Life Sciences Ltd. (Name of Issuer) $0 Par Value Ordinary Share (Title of Class of Securities) Y95308105 (CUSIP Number) January 23, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| January 9, 2023 |
Wave Life Sciences Corporate Presentation January 9, 2023 Exhibit 99.1 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commissio |
|
| December 22, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Wave Life Sciences Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) Y95308105 (CUSIP Number) December 12, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| December 19, 2022 |
EX-99.1 Exhibit 99.1 Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy 53% mean exon skipping and <1% (BLQ) mean dystrophin expression six weeks after initiating biweekly multidosing PN chemistry improved pharmacology of WVE-N531 compared with Wave’s first-generation DMD program – demonstrated high muscle concentrations with a mean of |
|
| December 19, 2022 |
EX-99.1 Exhibit 99.1 Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy 53% mean exon skipping and <1% (BLQ) mean dystrophin expression six weeks after initiating biweekly multidosing PN chemistry improved pharmacology of WVE-N531 compared with Wave’s first-generation DMD program – demonstrated high muscle concentrations with a mean of |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commiss |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of inc |
|
| December 13, 2022 |
EX-99.1 Exhibit 99.1 Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets Wave receives upfront payment of $170 million in cash and equity, also eligible to receive milestone payments and royalties Collaboration brings together Wave’s PRISMTM oligonucleotide platform and GSK’s expertise in genetics an |
|
| December 13, 2022 |
EX-99.2 Wave and GSK Collaboration December 13, 2022 Exhibit 99.2 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, col |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commiss |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Wave Life Sciences Ltd. (Name of Issuer) COM (Title of Class of Securities) Y95308105 (CUSIP Number) November 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| November 15, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commiss |
|
| November 15, 2022 |
Exhibit 99.1 Wave Life Sciences Corporate Presentation November 15, 2022 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development pla |
|
| November 10, 2022 |
Non-Employee Director Compensation Policy, as amended, effective as of August 15, 2022 Exhibit 10.1 Effective: Upon the date of receipt of final voting results (August 15, 2022) evidencing requisite shareholder approval of non-employee director compensation proposal at 2022 Annual General Meeting through 2023 Annual General Meeting WAVE Life Sciences Ltd. 2022 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY A. Introduction The Board of Directors (the ?Board?) of Wave Life Sciences Ltd. (t |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37627 WAVE LIF |
|
| November 10, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Wave Life Sciences Ltd. |
|
| November 10, 2022 |
As filed with the Securities and Exchange Commission on November 10, 2022 As filed with the Securities and Exchange Commission on November 10, 2022 Registration No. |
|
| November 10, 2022 |
Exhibit 99.1 Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update Announced positive update in third quarter from SELECT-HD trial in HD; single doses of WVE-003 appeared generally safe and well-tolerated and suggested allele-selective reduction of mHTT protein in CSF Multidosing underway in Phase 1b/2a trial of WVE-N531 in boys with DMD amenable to exon 53 s |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commiss |
|
| October 4, 2022 |
Exhibit 99.1 Wave Life Sciences Corporate Presentation October 4, 2022 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans |
|
| October 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commissio |
|
| September 28, 2022 |
Exhibit 99.1 Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event WVE-006 is the most advanced candidate for AATD designed to restore functional wild-type AAT protein and reduce Z-AAT protein aggregation with potential for disease modification in both lung and liver pheno |
|
| September 28, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commis |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commis |
|
| September 20, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commis |
|
| September 20, 2022 |
Exhibit 99.1 Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington?s Disease Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 or 60 mg; mean mHTT reduction across both cohorts was 22% (med |
|
| August 17, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commissio |
|
| August 17, 2022 |
Wave Life Sciences Corporate Presentation August 17, 2022 Exhibit 99.1 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commission |
|
| August 15, 2022 |
Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended (the “2021 Equity Plan”) Exhibit 10.1 Effective Date: August 9, 2022 WAVE LIFE SCIENCES LTD. 2021 EQUITY INCENTIVE PLAN, AS AMENDED 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the Wave Life Sciences Ltd. 2021 Equity Incentive Plan (the ?Plan?). The purposes of the Plan are to (i) provide eligible Employees, Consultants, and Directors with the opportunity to acquire a proprietary interest, or oth |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Information To Be Included in Statements Filed Pursuant to ? 240.13d-1(a) and Amendments Thereto Filed Pursuant to ? 240.13d-2(a) (Amendment No. 5)* WAVE Life Sciences Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) Ken Takanashi St. Luke?s Tower 12F, 8-1, Akashi-cho, |
|
| August 12, 2022 |
Exhibit 99.17 Further Deed of Charge of Shares Dated 15 May 2019 Between (1) Shin Nippon Biomedical Laboratories, Ltd. (Singapore Branch) (UEN No. T17FC0091B), which is registered as a foreign company in Singapore with its registered office at 51 Anson Road, #12-51 Anson Centre, Singapore 079904 (Chargor); (2) Kagoshima Bank, Ltd. (Registration No. 3400-01-000826), a Japanese banking corporation w |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37627 WAVE LIFE SCI |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commissio |
|
| August 11, 2022 |
Exhibit 99.1 Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023; first-in-class RNA editing candidate and most advanced program currently in development using an oligonucleotide to harness an endogenous enzyme for editing Data for ongoing clinical pro |
|
| August 11, 2022 |
Exhibit 10.1 733 CONCORD AVENUE CAMBRIDGE, MASSACHUSETTS (the ?Building?) SECOND AMENDMENT (?Second Amendment?) EXECUTION DATE: August 8, 2022 LANDLORD: CPI/King 733 Concord Owner, LLC, a Delaware limited liability company (as successor-in-interest to King 733 Concord LLC, a Delaware limited liability company) TENANT: Wave Life Sciences USA, Inc., a Delaware corporation EXISTING PREMISES: Approxim |
|
| July 20, 2022 |
SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* WAVE Life Sciences Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) Katsunori Nagakari 1-10 Yamanokuchi-cho, Kagoshima City, Kagoshima, 892-0844, Japan +81 99 295 6151 (Name, Address and Telephone Number of Perso |
|
| June 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| June 21, 2022 |
WVE / Wave Life Sciences Ltd / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response? 10.4 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Wave Life Sciences Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) RA Capital Management, L.P. |
|
| June 14, 2022 |
Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering Exhibit 99.1 Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering CAMBRIDGE, Mass., June 14, 2022 ? Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of an underwritten offering (the ?Offering?) of 25,464,483 of its ordinary s |
|
| June 14, 2022 |
Underwriting Agreement, dated June 14, 2022, by and between the Company and SVB Securities LLC. Exhibit 1.1 25,464,483 Ordinary Shares Pre-Funded Warrants to Purchase 7,093,656 Ordinary Shares Wave Life Sciences Ltd. UNDERWRITING AGREEMENT June 14, 2022 SVB SECURITIES LLC As Representative of the several Underwriters c/o SVB SECURITIES LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 Ladies and Gentlemen: Introductory. Wave Life Sciences Ltd. (Company Registration Number: 20121820 |
|
| June 14, 2022 |
EX-4.1 3 d364213dex41.htm EX-4.1 Exhibit 4.1 WAVE LIFE SCIENCES LTD. FORM OF PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES Number of Shares: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: [ ], 2022 Wave Life Sciences Ltd., a company incorporated under the laws of the Republic of Singapore (the “Company”), hereby certifies that, for good and valuable consideration, the receipt an |
|
| June 14, 2022 |
25,464,483 Ordinary Shares Pre-Funded Warrants to Purchase 7,093,656 Ordinary Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263251 PROSPECTUS SUPPLEMENT (To Prospectus dated May 4, 2022) 25,464,483 Ordinary Shares Pre-Funded Warrants to Purchase 7,093,656 Ordinary Shares We are offering 25,464,483 of our ordinary shares and, in lieu of ordinary shares to certain investors that so choose, pre-funded warrants to purchase 7,093,656 ordinary shares. Th |
|
| June 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commission |
|
| May 26, 2022 |
WVE / Wave Life Sciences Ltd / 683 Capital Management, LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. )* Wave Life Sciences Ltd. (Name of Issuer) $0 par value Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) May 16, 2022 (Date of Event which Req |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commission F |
|
| May 12, 2022 |
Description of Securities of the Registrant and Comparison of Shareholder Rights Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Wave Life Sciences Ltd. (the ?Company,? ?we,? ?us? or ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our ordinary shares, no par value. DESCRIPTION OF SHARE CAPITAL General The following description o |
|
| May 12, 2022 |
Exhibit 99.1 Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update Delivered first clinical data demonstrating target engagement and translation of PN chemistry?s impact in clinic; Adapting ongoing Phase 1b/2a FOCUS-C9 clinical trial to optimize dose level and frequency, with additional single and multidose data expected throughout 2022 Clinical data also exp |
|
| May 12, 2022 |
Exhibit 10.3 First Amendment To Collaboration and License Agreement This First Amendment (the ?First Amendment?) to that certain Collaboration Agreement (as defined below) is entered into as of August 4, 2020 (?First Amendment Effective Date?) by and among Wave Life Sciences USA, Inc., a corporation organized and existing under the Laws of the State of Delaware (?Wave US?), Wave Life Sciences UK L |
|
| May 12, 2022 |
Wave Life Sciences Corporate Presentation May 12, 2022 Exhibit 99.2 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, c |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37627 WAVE LIFE SC |
|
| May 2, 2022 |
WAVE LIFE SCIENCES LTD. 7 Straits View #12-00, Marina One East Tower Singapore 018936 WAVE LIFE SCIENCES LTD. 7 Straits View #12-00, Marina One East Tower Singapore 018936 May 2, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller RE: Wave Life Sciences Ltd. Registration Statement on Form S-3 Filed March 3, 2022 File No. 333-263251 Acceleration Request Dear Mr. Buchmiller: Wit |
|
| April 28, 2022 |
Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commission |
|
| April 4, 2022 |
Exhibit 99.1 Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004 Reductions in poly(GP), a key disease biomarker indicating target engagement, observed across all treatment groups after single doses Extending dose observation period from three months (day 85) to six months to identify |
|
| March 3, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commission |
|
| March 3, 2022 |
Exhibit 4.5 FORM OF SENIOR INDENTURE WAVE LIFE SCIENCES LTD., ISSUER and , TRUSTEE INDENTURE Dated as of , 20 Senior Debt Securities CROSS-REFERENCE TABLE1 Section of Trust Indenture Act Section of Section of of 1939, as amended Indenture 310(a) 7.09 310(b) 7.08, 7.10 310(c) Inapplicable 311(a) 7.13 311(b) 7.13 311(c) Inapplicable 312(a) 5.01, 5.02(a) 312(b) 5.02(c) 312(c) 5.02(c) 313(a) 5.04(a) 3 |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commission |
|
| March 3, 2022 |
Exhibit 10.1 AMENDMENT NO. 2 TO OPEN MARKET SALE AGREEMENT March 3, 2022 This Amendment No. 2 (?Amendment No. 2?) amends that certain Open Market Sale AgreementSM, dated as of May 10, 2019, as amended by Amendment No. 1, dated as of March 2, 2020 (together, the ?Agreement?), by and between Wave Life Sciences Ltd. (the ?Company?) and Jefferies LLC, as sales agent and/or principal (the ?Agent?). Def |
|
| March 3, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-3 Wave Life Sciences Ltd. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37627 WAVE LIFE SCIENCES LT |
|
| March 3, 2022 |
Exhibit 5.3 One Financial Center Boston, MA 02111 617 542 6000 mintz.com March 3, 2022 Wave Life Sciences Ltd. 7 Straits View #12-00, Marina One East Tower Singapore, 018936 Ladies and Gentlemen: We have acted as U.S. counsel to Wave Life Sciences Ltd., a company incorporated under the laws of Singapore (the ?Company?), in connection with the preparation and filing with the Securities and Exchange |
|
| March 3, 2022 |
Exhibit 10.3.2 Execution Version Second Amendment To Collaboration and License Agreement This Second Amendment (this ?Second Amendment?) to the Collaboration Agreement (as defined below) is entered into as of October 15, 2021 (?Second Amendment Effective Date?) by and among Wave Life Sciences USA, Inc., a corporation organized and existing under the Laws of the State of Delaware (?Wave US?), Wave |
|
| March 3, 2022 |
Wave Life Sciences Corporate Presentation March 3, 2022 Exhibit 99.2 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, |
|
| March 3, 2022 |
Description of Securities of the Registrant and Comparison of Shareholder Rights Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Wave Life Sciences Ltd. (the ?Company,? ?we,? ?us? or ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our ordinary shares, no par value. DESCRIPTION OF SHARE CAPITAL General The following description o |
|
| March 3, 2022 |
As filed with the Securities and Exchange Commission on March 3, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 3, 2022 Registration No. |
|
| March 3, 2022 |
Exhibit 99.1 Wave Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Clinical data from multiple novel, PN-modified stereopure oligonucleotides for ALS/FTD, DMD, and HD expected in 2022 GalNAc-AIMers restore therapeutically relevant levels of AAT for lung protection and reduce liver-damaging aggregates in preclinical study; IND enabling toxicolog |
|
| March 3, 2022 |
Form of Subordinated Indenture. Exhibit 4.6 FORM OF SUBORDINATED DEBT SECURITIES INDENTURE WAVE LIFE SCIENCES LTD. INDENTURE DATED AS OF , 20 TRUSTEE SUBORDINATED DEBT SECURITIES Table of Contents Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 4 ARTICLE II. SECURI |
|
| February 14, 2022 |
WVE / Wave Life Sciences Ltd / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* WAVE LIFE SCIENCES LTD. (Name of Issuer) $0 Par Value Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 14, 2022 |
EXHIBIT B Power of Attorney KNOW ALL MEN BY THESE PRESENTS, that I, Lee S. Ainslie III, hereby make, constitute and appoint Mark Gurevich as my agent and attorney-in -fact for the purpose of executing (i) in my personal capacity or (ii) in my capacity as manager or other officer or representative of Maverick Capital Management, LLC, Maverick Capital, Ltd. or any affiliate of either, all documents |
|
| February 14, 2022 |
WVE / Wave Life Sciences Ltd / MAVERICK CAPITAL LTD - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Wave Life Sciences Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 14, 2022 |
EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Ordinary Shares of Wave Life Sciences Ltd. |
|
| February 11, 2022 |
WVE / Wave Life Sciences Ltd / PFIZER INC - SC 13G/A WAVE LIFE SCIENCE LTD Passive Investment SC 13G/A 1 wave13gax2x22xvf.htm SC 13G/A WAVE LIFE SCIENCE LTD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) 1 Wave Life Sciences Ltd. (Name of Issuer) $0 par value Ordinary Shares (Titl |
|
| February 11, 2022 |
CUSIP No. Y95308105 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G to which this Agreement is annexed as Exhibit 99.1, and any amendments thereto, is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Dated: February 11, 2022 PFIZER INC. By: /s/ Su |
|
| February 11, 2022 |
WVE / Wave Life Sciences Ltd / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* WAVE LIFE SCIENCES LTD. (Name of Issuer) Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 11, 2022 |
WVE / Wave Life Sciences Ltd / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Wave Life Sciences Ltd. (Name of Issuer) COM (Title of Class of Securities) Y95308105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 10, 2022 |
Wave Life Sciences Investor Presentation January 10, 2022 Exhibit 99.1 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commissi |
|
| November 12, 2021 |
WVE / Wave Life Sciences Ltd / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Wave Life Sciences Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) Y95308105 (CUSIP Number) RA Capital Management, L.P. |
|
| November 10, 2021 |
Form of Inducement Restricted Share Unit Agreement Exhibit 10.7 Grant. No. RSU- Wave Life Sciences Ltd. (the ?Company?) Nasdaq Inducement Restricted Share Unit Award Grant Notice and Nasdaq Inducement Restricted Share Unit Agreement A. Name of Participant: B. Grant Date: C. Maximum Number of Shares Underlying Restricted Share Unit Award: D. Vesting Start Date: E. Vesting Schedule: This Restricted Share Unit Award shall vest as follows provided the |
|
| November 10, 2021 |
Exhibit 99.1 Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update Strengthened balance sheet with approximately $52 million; focusing additional investment in RNA editing programs led by hepatic editing Optimized AIMers for AATD program demonstrate potent, highly specific RNA editing and restoration of functional AAT protein substantially above therapeutic t |
|
| November 10, 2021 |
Non-Employee Director Compensation Policy, as amended, effective as of August 16, 2021 Exhibit 10.1 Effective: Upon the date of receipt of final voting results (August 16, 2021) evidencing requisite shareholder approval of non-employee director compensation proposal at 2021 Annual General Meeting through 2022 Annual General Meeting WAVE Life Sciences Ltd. 2021 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY A. Introduction The Board of Directors (the ?Board?) of Wave Life Sciences Ltd. (t |
|
| November 10, 2021 |
Exhibit 10.6 Grant. No. RSU- Wave Life Sciences Ltd. 2021 EQUITY INCENTIVE PLAN Restricted Share Unit Award Grant Notice for Restricted Share Unit Agreement (for UK Participants) A. Name of Participant: B. Grant Date: C. Maximum Number of Shares Underlying Restricted Share Unit Award: D. Vesting Start Date: E. Vesting Schedule: This Restricted Share Unit Award shall vest as follows provided the Pa |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commiss |
|
| November 10, 2021 |
Wave Life Sciences Ltd. 2021 Equity Incentive Plan (the “2021 Equity Plan”) Exhibit 10.2 Effective Date: August 10, 2021 WAVE LIFE SCIENCES LTD. 2021 EQUITY INCENTIVE PLAN 1.Purpose; Eligibility. 1.1General Purpose. The name of this plan is the Wave Life Sciences Ltd. 2021 Equity Incentive Plan (the ?Plan?). The purposes of the Plan are to (i) provide eligible Employees, Consultants, and Directors with the opportunity to acquire a proprietary interest, or otherwise increa |
|
| November 10, 2021 |
Form of Restricted Share Unit Agreement under the 2021 Equity Plan, effective as of August 10, 2021 Exhibit 10.4 Grant. No. RSU- Wave Life Sciences Ltd. 2021 EQUITY INCENTIVE PLAN Restricted Share Unit Award Grant Notice for Restricted Share Unit Agreement A. Name of Participant: B. Grant Date: C. Maximum Number of Shares Underlying Restricted Share Unit Award: D. Vesting Start Date: E. Vesting Schedule: This Restricted Share Unit Award shall vest as follows provided the Participant remains in C |
|
| November 10, 2021 |
Exhibit 10.5 Grant No. Wave Life Sciences Ltd. 2021 EQUITY INCENTIVE PLAN Non-qualified Share Option Grant Notice Under the Company?s Non-qualified Share Option Agreement (for UK Participants) A. Name of Participant: B. Grant Date: [For employees: C. Expiration Date: 10-year anniversary of the Grant Date [For any non-employees: C. Expiration Date: 5-year anniversary of the Grant Date D. Maximum Nu |
|
| November 10, 2021 |
As filed with the Securities and Exchange Commission on November 10, 2021 As filed with the Securities and Exchange Commission on November 10, 2021 Registration No. |
|
| November 10, 2021 |
Wave Life Sciences Corporate Presentation November 10, 2021 Exhibit 99.2 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development pla |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37627 WAVE LIF |
|
| November 10, 2021 |
Exhibit 10.3 Grant No. Wave Life Sciences Ltd. 2021 EQUITY INCENTIVE PLAN Non-qualified Share Option Grant Notice Under the Company?s Non-qualified Share Option Agreement A.Name of Participant: B.Grant Date: [For employees: C.Expiration Date: 10-year anniversary of the Grant Date [For any non-employees: C.Expiration Date: 5-year anniversary of the Grant Date D.Maximum Number of Ordinary Shares for |
|
| October 29, 2021 |
WVE / Wave Life Sciences Ltd / M28 Capital Management LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2021 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commissi |
|
| October 18, 2021 |
Exhibit 99.1 Wave Life Sciences and Takeda Amend CNS Collaboration Amendment to ongoing collaboration allows Wave to advance or partner CNS programs, including those using ADAR editing Takeda option to co-develop and co-commercialize late-stage CNS programs, including clinical programs WVE-004 and WVE-003, remains unchanged CAMBRIDGE, Mass., October 18, 2021 ? Wave Life Sciences Ltd. (Nasdaq: WVE) |
|
| September 28, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2021 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 001-37627 00-0000000 (State or other jurisdiction of incorporation) (Commis |
|
| September 28, 2021 |
EX-99.2 3 d210199dex992.htm EX-99.2 Exhibit 99.2 Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues and Provides Update on AATD Program During Analyst and Investor Research Webcast Durable ADAR editing in vivo in preclinical models, including in CNS tissues with editing out to at least four months Chemistry optimization yields a four-fold increase over |
|
| September 28, 2021 |
EX-99.1 2 d210199dex991.htm EX-99.1 Exhibit 99.1 Analyst & Investor Research Webcast September 28, 2021 1 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strateg |
